p.6 抽出テキスト

Figure 20 Cardiovascular surveillance in patients treated with immune checkpoint inhibitors ................................................................... 4273 Figure 21 Androgen deprivation therapy-related cardiovascular toxicities .............................................................................................................. 4275 Figure 22 Anaplastic lymphoma kinase and epidermal growth factor receptor inhibitor-related cardiovascular toxicities ........... 4278 Figure 23 Radiotherapy mean heart dose and associated cardiovascular toxicity risk .......................................................................... 4280 Figure 24 Risk factors and cardiovascular surveillance in patients referred for haematopoietic stem cell transplantation .................. 4281 Figure 25 Management of anthracycline chemotherapy-related cardiac dysfunction ......................................................................................... 4283 Figure 26 Management of human epidermal receptor 2-targeted therapy-related cardiac dysfunction ........................................................ 4285 Figure 27 Direct and indirect immune checkpoint inhibitor-related cardiovascular toxicity ................................................ 4287 Figure 28 Diagnosis and management of immune checkpoint inhibitor-related myocarditis ...................................................................... 4288 Figure 29 Diagnosis and management workup in cancer-related Takotsubo syndrome .................................................................................... 4290 Figure 30 Pathophysiology of atrial fibrillation associated with cancer ................................................................................................................... 4295 Figure 31 Structured approach to anticoagulation for atrial fibrillation in patients with cancer ............................................................ 4296 Figure 32 Corrected QT interval monitoring before and during treatment with corrected QT interval-prolonging anticancer drugs 4299 Figure 33 Recommended threshold for asymptomatic hypertension treatment in different clinical scenarios .................... 4301 Figure 34 Treatment of arterial hypertension in patients with cancer ................................................................................................................... 4302 Figure 35 Risk factors for venous thromboembolism in patients with cancer ........................................................................................................ 4303 Figure 36 Structured approach to anticoagulation for venous thromboembolism in patients with active cancer ............................ 4304 Figure 37 Management of cancer therapy-related cardiac dysfunction after cancer therapy ............................................................. 4311 Figure 38 Long-term follow-up in cancer survivors ......................... 4315 Figure 39 Location of primary and secondary cardiac tumours . 4320 Figure 40 Diagnostic algorithm for cardiac masses .......................... 4321 Figure 41 Cardiac monitoring protocol for pregnant women receiving anthracycline-based chemotherapy ..................................... 4322 Figure 42 Carcinoid heart disease: clinical features and diagnostic tests ....................................................................................................................... 4324 Figure 43 Non-invasive diagnosis of amyloid light-chain cardiac amyloidosis ......................................................................................................... 4325 Figure 44 Risk stratification in patients with a cardiac implantable electronic device undergoing radiotherapy ......................................... 4327 Figure 45 Management of patients with a cardiac implantable electronic device located in the radiotherapy treatment beam . 4328 Figure 46 Management of patients with a cardiac implantable electronic device located outside the radiotherapy treatment volume ................................................................................................................. 4329 Figure 47 Patient information, communication, and self-management .............................................................................................. 4330 Figure 48 The role of scientific societies in the promotion and development of cardio-oncology ............................................................. 4331 Abbreviations and acronyms

2D Two-dimensional 3D Three-dimensional 5-FU 5-fluorouracil 5HIAA 5-hydroxyindoleacetic acid a′ Late diastolic velocity of mitral annulus obtained by tissue Doppler imaging ABC Atrial fibrillation Better Care ABI Ankle–brachial index AC Anthracycline chemotherapy ACE-I Angiotensin-converting enzyme inhibitors ACS Acute coronary syndromes ADT Androgen deprivation therapy ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AF Atrial fibrillation AI Aromatase inhibitors AL-CA Amyloid light-chain cardiac amyloidosis ALK Anaplastic lymphoma kinase ANS Autonomic nervous system ARB Angiotensin receptor blockers ARISTOTLE Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ASCVD AtheroSclerotic Cardiovascular Disease ASPIRE Carfilzomib, Lenalidomide, and Dexamethasone vs. Lenalidomide and Dexamethasone for the Treatment of Patients with Relapsed Multiple Myeloma ASTCT American Society for Transplantation and Cellular Therapy ATAC ‘Arimidex’ and Tamoxifen Alone or in Combination ATE Arterial thromboembolism AV Atrioventricular BB Beta-blockers BC Breast cancer BCR-ABL Breakpoint cluster region–Abelson oncogene locus BIG Breast International Group BLEED Increased bleeding risk BMI Body mass index BNP B-type natriuretic peptide BP Blood pressure BTK Bruton tyrosine kinase C Chemotherapy cycle CABG Coronary artery bypass graft CAD Coronary artery disease CARDIOTOX CARDIOvascular TOXicity induced by cancer-related therapies CAR-T Chimeric antigen receptor T cell CCB Calcium channel blockers CCS Chronic coronary syndromes CCTA Coronary computed tomography angiography Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026